Haloperidol vs Conventional Therapy for Gastroparesis (HATGAS)
Gastroparesis
About this trial
This is an interventional treatment trial for Gastroparesis
Eligibility Criteria
Inclusion Criteria:
- Previous diagnosis of GP including those without formal gastric emptying studies.
- Patients presenting with unresolving nausea, vomiting, and abdominal pain that is attributable to their GP.
Exclusion Criteria:
- History of QT prolongation or presence on a 12 leads electrocardiogram.
- Presence of concomitant acute abdominal pathology including but not limited to hepatobiliary disease, ischemia, and abdominal aneurysm.
- Prisoners
- Hypotension (systolic blood pressure below 90 mm Hg)
- Pregnant women
- Patients who are cognitively impaired and/or unable to consent for the study
- Age <18
- Allergy to haloperidol
Sites / Locations
- Lyndon Baines Johnson General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Haloperidol plus Conventional Therapy
Conventional Therapy alone
Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.